Healthcare staffing company AMN Healthcare Services (NYSE: AMN) beat Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 11.1% year on year to $658.2 million. On the other hand, next quarter’s revenue guidance of $617.5 million was less impressive, coming in 3.7% below analysts’ estimates. Its non-GAAP profit of $0.30 per share was 60.9% above analysts’ consensus estimates.

Is now the time to buy AMN? Find out in our full research report (it’s free).

StockStory’s Take

AMN Healthcare Services’ second quarter results received a positive market reaction, supported by performance that exceeded Wall Street’s revenue and non-GAAP profit expectations. Management attributed the quarter’s outcome to a combination of persistent softness in healthcare staffing orders, especially among academic medical centers, and ongoing cost control initiatives. CEO Cary Grace noted, “Uncertainty about government policy impact placed the healthcare sector in a more cautious stance... directly impacting our industry.” Notably, stabilization in gross margins and operational improvements helped counterbalance lower sales volumes and sector-wide demand challenges.

For the upcoming quarters, AMN’s guidance reflects persistent headwinds, with expectations for muted revenue growth as the healthcare staffing environment adjusts to new policy realities and shifting client priorities. Management emphasized stabilization in extension rates and order volumes, but also acknowledged ongoing pressure from clients’ cost containment efforts. Grace commented, “We are seeing some of the delayed decision-making really start to break free a little bit as we've entered the third quarter,” but warned that meaningful volume recovery may not materialize until later in the year, especially as academic medical centers and other large clients gradually adjust their hiring strategies.

Key Insights from Management’s Remarks

Management pointed to several evolving dynamics behind the quarter’s performance, including policy uncertainty, segment-specific trends, and the impact of technology and efficiency initiatives.

• Policy and funding uncertainty: Clients, particularly academic medical centers, delayed staffing decisions in response to government policy changes and funding reductions. Management noted this led to reduced staffing orders and lower extension rates, especially in travel nursing.
• Technology-driven efficiencies: Operational speed and automation initiatives, including the rollout of AMN Passport and expanded AI capabilities, drove improvements in fill rates and user engagement. Over 20% of Nurse and Allied placements are now assisted by Passport automation, supporting cost control and efficiency gains.
• Segment performance divergence: While Travel Nurse volumes continued to decline, Allied staffing orders showed resilience, buoyed by demand in outpatient therapy and imaging. Management expects the Allied Schools business to deliver double-digit volume growth in the fourth quarter due to strong bookings.
• Competitive landscape and consolidation: AMN retained market share in a fragmented, competitive environment and anticipates further industry consolidation. Management views current competitor struggles and emerging consolidation as opportunities for incremental share gains, particularly through differentiated offerings like labor disruption support.
• Strategic divestiture and capital allocation: The sale of the Smart Square scheduling software was framed as a move to focus capital on higher-growth areas and enable broader partnerships within workforce planning and scheduling, rather than competing directly in scheduling software.

Drivers of Future Performance

AMN’s outlook is shaped by cautious client spending, gradual stabilization in demand, and an emphasis on technology-enabled solutions to drive future growth and profitability.

• Client demand normalization: Management expects client demand for contingent staffing to remain stable but at lower levels, citing that spending on premium staffing has normalized and future growth will depend on broader adoption of flexible workforce solutions and data-driven program management.
• International and segment recovery: The international nurse staffing segment is projected to return to positive growth in the fourth quarter, with management expecting double-digit gains in both revenue and EBITDA for this business in 2026 as visa processing improves. Allied Schools and locum tenens are also expected to contribute to growth as order pipelines strengthen.
• Operational and pricing discipline: Cost management through automation and technology will remain a core focus, but competitive pricing pressures—particularly in Language Services—could weigh on margins. Management believes maintaining operational efficiency and adapting to evolving client models (such as supplier-led MSPs) will be key to sustaining profitability.

Catalysts in Upcoming Quarters

In the coming quarters, StockStory analysts will be monitoring (1) the pace of recovery in staffing volumes, especially among academic medical centers and international nurse placements, (2) stabilization or improvement in extension rates and new order activity for nurse and allied staffing, and (3) the impact of technology investments like Passport and AI automation on operational efficiency and fill rates. Execution on pipeline opportunities and further industry consolidation will also be critical signposts.

AMN Healthcare Services currently trades at $16.62, down from $16.89 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.